ArticlemedRxiv : the preprint server for health sciences2026
Location patterns and longitudinal progression of white matter hyperintensities.
Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objectives: White matter hyperintensities (WMH) of presumed vascular origin are a neuroimaging hallmark of cerebral small vessel disease (CSVD). Their spatial heterogeneity may reflect different clinical phenotypes. Most prior studies relied on principal component analysis to characterise such heterogeneity, which has limited ability to stratify individuals into discrete and interpretable WMH subtypes. We therefore propose a data-driven framework to identify WMH spatial subtypes, characterise their demographic and clinical profiles, and investigate their predictive value for future WMH progression. Methods: We analysed MRI scans from 63,338 individuals across 4 major cohorts (internal data): ADNI3, Insight46, SABRE and UK Biobank (UKB), and validated our findings in the OASIS-3 dataset (n=844). WMH were automatically segmented and regionally quantified using a 36-region bullseye framework. Clustering was applied to the relative regional distributions of WMH. A stability-based approach was used to identify robust WMH subtypes. Their associations with 19 risk factors of interest were analysed using multivariable regression. In a subset with follow-up MRI scans (internal: n=5,274, OASIS-3: n=182), we evaluated the predictive value of these subtypes combined with other volumetric or spatial WMH variables for WMH progression. Results: Five WMH location patterns with different lesion burden and spatial distribution were identified (stability score 0.946) and reproduced in OASIS-3. These patterns showed distinct associations with demographic, vascular, metabolic, inflammatory and genetic risk factors. Higher-burden patterns were independently associated with older age, higher blood pressure, diabetes and smoking, indicating a gradient of vascular risk across spatial subtypes. WMH location patterns were largely preserved over 18-30 months, with most individuals remaining within the same pattern (71.5%). While global baseline WMH volume remained a strong predictor of future WMH progression (balanced accuracy 0.693, 95% CI: 0.664-0.723), models including baseline regional WMH volumes consistently outperformed other candidates (best balanced accuracy 0.737, 95% CI: 0.706-0.764). Discussion: We presented a robust and scalable framework for spatial WMH phenotyping. We discussed clinical and prognostic implications of the spatial subtypes beyond total lesion burden. Our findings supported the value of WMH spatial characterisation in stratifying risk that may help guide personalised approaches to managing CSVD.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.